STOCKHOLM, Sweden, March 3, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia has declined the approval of lecanemab (generic name) as a treatment for early Alzheimer's...
Hence then, the article about therapeutic goods administration decides not to register lecanemab in australia was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Therapeutic Goods Administration decides not to register lecanemab in Australia )
Also on site :
- Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
- Andrew Scott & George MacKay Lead Voice Cast Of Russell Tovey’s Debut Novel ‘Starlings’, Which Is Being Published By Audible
- Global Waste-derived Pyrolysis Oil Market Report 2026 .. Asia Pacific Leads Demand While Shell, BASF and Agilyx Compete in Circular Polymer Feedstock